Trial · NCT04501679
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With an Improvement of Greater Than or Equal to (>=) 4 From Baseline in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16 | Nemolizumab | 103 | Participants | ||
| Number of Participants With an Improvement of Greater Than or Equal to (>=) 4 From Baseline in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16 | Placebo | 19 | Participants | ||
| Number of Participants With an Investigator Global Assessment (IGA) Success at Week 16 | Nemolizumab | 69 | Participants | ||
| Number of Participants With an Investigator Global Assessment (IGA) Success at Week 16 | Placebo | 10 | Participants | ||
| Number of Participants With an Improvement of >= 4 From Baseline in Weekly Average PP NRS at Week 4 | Nemolizumab | 75 | Participants | ||
| Number of Participants With an Improvement of >= 4 From Baseline in Weekly Average PP NRS at Week 4 | Placebo | 7 | Participants | ||
| Number of Participants With PP NRS < 2 at Week 16 | Nemolizumab | 64 | Participants | ||
| Number of Participants With PP NRS < 2 at Week 16 | Placebo | 7 | Participants | ||
| Number of Participants With an Improvement of >=4 From Baseline in Sleep Disturbance Numeric Rating Scale (SD NRS) at Week 16 | Nemolizumab | 95 | Participants | ||
| Number of Participants With an Improvement of >=4 From Baseline in Sleep Disturbance Numeric Rating Scale (SD NRS) at Week 16 | Placebo | 19 | Participants | ||
| Number of Participants With an Improvement of >=4 From Baseline in SD NRS at Week 4 | Nemolizumab | 68 | Participants | ||
| Number of Participants With an Improvement of >=4 From Baseline in SD NRS at Week 4 | Placebo | 9 | Participants | ||
| Number of Participants With PP NRS < 2 at Week 4 | Nemolizumab | 36 | Participants | ||
| Number of Participants With PP NRS < 2 at Week 4 | Placebo | 2 | Participants | ||
| Number of Participants With Adverse Events, Treatment Emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESIs), and Serious Adverse Events (SAEs) | Nemolizumab | Treatment Emergent Adverse Events (TEAEs) | 112 | Participants | |
| Number of Participants With Adverse Events, Treatment Emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESIs), and Serious Adverse Events (SAEs) | Placebo | Treatment Emergent Adverse Events (TEAEs) | 48 | Participants | |
| Number of Participants With Adverse Events, Treatment Emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESIs), and Serious Adverse Events (SAEs) | Nemolizumab | Adverse Events of Special Interest (AESIs) | 21 | Participants | |
| Number of Participants With Adverse Events, Treatment Emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESIs), and Serious Adverse Events (SAEs) | Placebo | Adverse Events of Special Interest (AESIs) | 9 | Participants | |
| Number of Participants With Adverse Events, Treatment Emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESIs), and Serious Adverse Events (SAEs) | Nemolizumab | Serious Adverse Events (SAEs) | 4 | Participants | |
| Number of Participants With Adverse Events, Treatment Emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESIs), and Serious Adverse Events (SAEs) | Placebo | Serious Adverse Events (SAEs) | 5 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04501679/results